Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label?
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Inc. (ARWR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 1,500,000 | $1,543,050 | 0.69% | ||
| 2. | 994,000 | $1,027,374 | -24% | 0.04% | |
| 3. | Laurion Capital Management Benjamin A. Smith | 3,484 | $228,028 | -12% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.00 | 500 | $11,000.00 | 36,080 | 2024-04-18 | Filing | |
| $25.00 | 500 | $12,500.00 | 35,580 | 2024-04-10 | Filing | |
| $27.34 | 150 | $4,101.00 | 35,080 | 2024-04-02 | Filing | |
| $27.50 | 850 | $23,375.00 | 34,930 | 2024-03-26 | Filing | |
| $28.00 | 400 | $11,200.00 | 34,080 | 2024-03-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.96 | 2,000 | $173,920.00 | 31,600 | 2026-08-18 | Filing | |
| $87.30 | 11,600 | $1,012,680.00 | 111,459 | 2026-08-18 | Filing | |
| $76.88 | 2,970 | $228,333.60 | 52,012 | 2026-05-12 | Filing | |
| $71.92 | 8,730 | $627,861.60 | 162,905 | 2026-04-22 | Filing | |
| $70.45 | 1,157 | $81,510.65 | 171,635 | 2026-04-22 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 820,239 | $53,684,643 | 17.87% | |
| 2. | 27,193,000 | $27,836,761 | 1.01% | |
| 3. | 186,267 | $12,191,175 | 0.14% | |
| 4. | 173,286 | $11,341,569 | 0.11% | |
| 5. | 147,200 | $9,634,240 | 2.61% |
News See All
Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating?
Arrowhead Pharmaceuticals, Inc.
Arrowhead (ARWR) Soars to New High as Plozasiran Nears Expanded Commercialization
Arrowhead Pharmaceuticals Inc.
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech's Solid Start to 2026
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the best medical stocks to invest in according to billionaires. Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2026 Earnings Call Transcript May 7, 2026Arrowhead Pharmaceuticals, Inc. beats earnings expectations.
Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) ranks among the most profitable biotech stocks to buy now. Following comments on Arrowhead Pharmaceuticals Inc.
10 Most Profitable Biotech Stocks to Buy Now
In this article, we will take a look at the 10 Most Profitable Biotech Stocks to Buy Now.
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of Billionaire Ken Fisher’s 15 Most Notable Moves for 2026. Arrowhead Pharmaceuticals, Inc.
Billionaire Ken Fisher's 15 Most Notable Moves for 2026
For many Wall Street investors, it is their first time navigating market uncertainty at a time of geopolitical upheaval.
Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one of the best multibagger stocks to invest in according to billionaires.
Hedge Fund Resource Center